Cited by 135Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingNerve injury and regeneration

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons

Porritt, M.J., Batchelor, P.E., Howells, D.W·2005·Experimental Neurology

DOI 10.1016/j.expneurol.2004.11.030

Open this paper in CoChat — free account

Abstract

Brain derived neurotrophic factor (BDNF) expression is significantly reduced in the Parkinson's disease substantia nigra. This neurotrophin has potent affects on dopaminergic neuron survival protecting them from the neurotoxins MPTP and 6-hydroxydopamine (6-OHDA) commonly used to create animal models of Parkinson's disease and also promoting dopaminergic axonal sprouting. In this study, we demonstrate that an antisense oligonucleotide infusion (200 nM for 28 days) to prevent BDNF production in the substantia nigra of rats mimics many features of the classical animal models of Parkinson's disease. 62% of antisense treated rats rotate (P < or = 0.05) in response to dopaminergic receptor stimulation by apomorphine. 40% of substantia nigra pars compacta tyrosine hydroxylase immunoreactive neurons are lost (P < or = 0.00001) and dopamine uptake site density measured by (3)H-mazindol autoradiography is reduced by 34% (P < or = 0.005). Loss of haematoxylin and eosin stained nigral neurons is significant (P < or = 0.0001) but less extensive (34%). These observations indicate that loss of BDNF expression leads both to down regulation of the dopaminergic phenotype and to dopaminergic neuronal death. Therefore, reduced BDNF mRNA expression in Parkinson's disease substantia nigra may contribute directly to the death of nigral dopaminergic neurons and the development of Parkinson's disease.

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2004.11.030

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system
Ungerstedt, U., & Arbuthnott, G. W. (1970) · Brain Research · doi:10.1016/0006-8993(70)90187-3 · Cited by 1,995
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,503
Adipsia and Aphagia after 6‐Hydroxydopamine Induced Degeneration of the Nigro‐striatal Dopamine System
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb11001.x · Cited by 1,294
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments
Schwarting, R. K. W., & Huston, J. P. (1996) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00040-8 · Cited by 741
Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor
Batchelor, P., Liberatore, G. T., Wong, J. Y. F., Porritt, M. J., Frerichs, F., Donnan, G. A., & Howells, D. W. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-05-01708.1999 · Cited by 576
Self-citation
Human and rat brain-derived neurotrophic factor and neurotrophin-3: Gene structures, distributions, and chromosomal localizations
Maisonpierre, P. C., Beau, M. M. L., Espinosa, R., Ip, N. Y., Belluscio, L., de la Monte, S. M., Squinto, S. P., Furth, M. E., & Yancopoulos, G. D. (1991) · Genomics · doi:10.1016/0888-7543(91)90436-i · Cited by 514
Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra
Howells, D. W., Porritt, M. J., Wong, J. Y. F., Batchelor, P. E., Kalnins, R., Hughes, A. J., & Donnan, G. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7483 · Cited by 513
Self-citation
BDNF and NT-4/5 Prevent Atrophy of Rat Rubrospinal Neurons after Cervical Axotomy, Stimulate GAP-43 and Tα1-Tubulin mRNA Expression, and Promote Axonal Regeneration
Kobayashi, N., Fan, D.-P., Giehl, K. M., Bedard, A. M., Wiegand, S. J., & Tetzlaff, W. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-24-09583.1997 · Cited by 476
Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression
Eisch, A. J., Bolaños, C. A., de Wit, J., Simonak, R. D., Pudiak, C. M., Barrot, M., Verhaagen, J., & Nestler, E. J. (2003) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.003 · Cited by 420
Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease
Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., & Nagatsu, T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00463-2 · Cited by 404
Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.
Brown, D. A., Kang, S. H., Gryaznov, S. M., DeDionisio, L., Heidenreich, O. T., Sullivan, S., Xu, X., & Nerenberg, M. I. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47090-1 · Cited by 336
Neurotrophin trafficking by anterograde transport
Altar, C. A., & DiStefano, P. S. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01273-9 · Cited by 319
Reduced expression of brain-derived neurotrophic factor protein in Parkinsonʼs disease substantia nigra
Parain, K., Murer, M. G., Yan, Q., Faucheux, B. A., Agid, Y., Hirsch, É. C., & Raisman‐Vozari, R. (1999) · Neuroreport · doi:10.1097/00001756-199902250-00021 · Cited by 303
Dopaminergic neurons in rat ventral midbrain express brain‐derived neurotrophic factor and neurotrophin‐3 mRNAs
Seroogy, K. B., Lundgren, K. H., Tran, T. M., Guthrie, K. M., Isackson, P. J., & Gall, C. M. (1994) · The Journal of Comparative Neurology · doi:10.1002/cne.903420302 · Cited by 299
Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease
Levivier, M., Przedborski, S., Bencsics, C., & Kang, U. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-12-07810.1995 · Cited by 274
BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration
Siuciak, J. A., Boylan, C. B., Fritsche, M., Altar, C. A., & Lindsay, R. M. (1996) · Brain Research · doi:10.1016/0006-8993(95)01289-3 · Cited by 236
Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior
Carman, L. S., Gage, F. H., & Shults, C. W. (1991) · Brain Research · doi:10.1016/0006-8993(91)90835-j · Cited by 231
Axonal sprouting following lesions of the rat substantia nigra
Finkelstein, D. I., Stanić, D., Parish, C. L., Tomas, D., Dickson, K. A., & Horne, M. K. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00009-9 · Cited by 201
Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system.
Whitesell, L. J., Geselowitz, D. A., Chavany, C., Fahmy, B., Walbridge, S., Alger, J. R., & Neckers, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4665 · Cited by 183
Interdependence of the Nigrostriatal Dopaminergic Systems on the Two Sides of the Brain in the Cat
Nieoullon, A. L., Chéramy, A., & Glowinski, J. (1977) · Science · doi:10.1126/science.910137 · Cited by 183
Biochemistry of Parkinson's disease 28 years later: A critical review
Agid, Y., Cervera, P., Hirsch, É. C., Javoy-Agid, F., Lehericy, S., Raisman‐Vozari, R., & Ruberg, M. (1989) · Movement Disorders · doi:10.1002/mds.870040514 · Cited by 162
COMPARATIVE STUDY OF BRAIN-DERIVED NEUROTROPHIC FACTOR MESSENGER RNA AND PROTEIN AT THE CELLULAR LEVEL SUGGESTS MULTIPLE ROLES IN HIPPOCAMPUS, STRIATUM AND CORTEX
Schmidt‐Kastner, R., Wetmore, C., & OLSON, L. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00093-0 · Cited by 139
Efficacy of Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 on Neurochemical and Behavioral Deficits Associated with Partial Nigrostriatal Dopamine Lesions
Altar, C. A., Boylan, C. B., Fritsche, M., Jones, B. E., Jackson, C., Wiegand, S. J., Lindsay, R. M., & Hyman, C. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63031021.x · Cited by 138
Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys
Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N. (1995) · Neurosurgery · doi:10.1227/00006123-199510000-00018 · Cited by 134
Developmental Regulation of Early Serotonergic Neuronal Differentiation: The Role of Brain-Derived Neurotrophic Factor and Membrane Depolarization
Eaton, M. J., Staley, J. K., Globus, M. Y. ‐., & Whittemore, S. R. (1995) · Developmental Biology · doi:10.1006/dbio.1995.1205 · Cited by 128
The Neurotrophins NT-4/5 and BDNF Augment Serotonin, Dopamine, and GABAergic Systems during Behaviorally Effective Infusions to the Substantia Nigra
Altar, C. A., Boylan, C. B., Fritsche, M., Jackson, C., Hyman, C., & Lindsay, R. M. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1182 · Cited by 116
Grafts of BDNF-Producing Fibroblasts Rescue Axotomized Rubrospinal Neurons and Prevent Their Atrophy
Liu, Y. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7977 · Cited by 114
Behavioral and neuronal reorganization after unilateral substantia nigra lesions: Evidence for increased interhemispheric nigrostriatal projections
Pritzel, M., Huston, J. P., & Sarter, M. F. (1983) · Neuroscience · doi:10.1016/0306-4522(83)90276-2 · Cited by 106
Inhibition of brain‐derived neurotrophic factor and glial cell line‐derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum
Batchelor, P., Liberatore, G. T., Porritt, M. J., Donnan, G. A., & Howells, D. W. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00239.x · Cited by 105
Self-citation
BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine
Shults, C. W., Kimber, T. A., & Altar, A. C. (1995) · Neuroreport · doi:10.1097/00001756-199505300-00009 · Cited by 83
Adeno-associated viral vector-mediated gene transfer of brain-derived neurotrophic factor reverses atrophy of rubrospinal neurons following both acute and chronic spinal cord injury
Ruitenberg, M. J., Blits, B., Dijkhuizen, P. A., Beek, E. T. T., Bakker, A., van Heerikhuize, J. J., Pool, C. W., Hermens, W. T. J., Boer, G. J., & Verhaagen, J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.11.018 · Cited by 80
Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphé serotonergic neurons
Celada, P., Siuciak, J. A., Tran, T. M., Altar, C. A., & Tepper, J. M. (1996) · Brain Research · doi:10.1016/0006-8993(95)01469-1 · Cited by 74
Effects of BDNF and NT‐4/5 on Striatonigral Neuropeptides or Nigral GABA Neurons In Vivo
Arenas, E., Åkerud, P., Wong, V., Boylan, C. B., Person, H., Lindsay, R. M., & Altar, C. A. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01314.x · Cited by 67
Alterations in Nigrostriatal Dopaminergic Function within BDNF Mutant Mice
Dluzen, D. E., Story, G. M., Xu, K., Kučera, J., & Walro, J. M. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7225 · Cited by 65
Effects of unilateral electrical stimulation of various thalamic nuclei on the release of dopamine from dendrites and nerve terminals of neurons of the two nigrostriatal dopaminergic pathways
Chéramy, A., Chesselet, M., Romo, R., Leviel, V., & Glowinski, J. (1983) · Neuroscience · doi:10.1016/0306-4522(83)90008-8 · Cited by 64
Experimental models and behavioural tests used in the study of Parkinson's disease.
Mokrý, J. (1995) · PubMed · Cited by 57
Opposing effects of morphine and the neurotrophins, NT-3, NT-4, and BDNF, on locus coeruleus neurons in vitro
Sldair-Tavron, L., & Nestler, E. J. (1995) · Brain Research · doi:10.1016/0006-8993(95)01029-8 · Cited by 56
Design and application of antisense oligonucleotides in cell culture,in vivo, and as therapeutic agents
Brysch, W., & Schlingensiepen, K. (1994) · Cellular and Molecular Neurobiology · doi:10.1007/bf02088837 · Cited by 54
Neurochemical evidence for histamine acting as a transmitter in mammalian brain.
Schwartz, J., Barbin, G., Bm, G., Pollard, H., Rose, C., & Verdière‐Sahuqué, M. (1976) · PubMed · Cited by 51
Functional Neuropathology in Parkinson's Disease
Gibb, W. R. G. (2008) · European Neurology · doi:10.1159/000113472 · Cited by 50
Compensatory bilateral changes in dopamine turnover after striatal kainate lesion
Andersson, K., Schwarcz, R. M., & Fuxé, K. (1980) · Nature · doi:10.1038/283094a0 · Cited by 49
Behavioral indices of moderate nigro‐striatal 6‐hydroxydopamine lesion: A preclinical Parkinson's model
Fornaguera, J., Schwarting, R. K. W., Boix, F., & Huston, J. P. (1993) · Synapse · doi:10.1002/syn.890130209 · Cited by 48
Expression of Brain-Derived Neurotrophic Factor and TrkB Neurotrophin Receptors after Striatal Injury in the Mouse
Wong, J. Y. F., Liberatore, G. T., Donnan, G. A., & Howells, D. W. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6670 · Cited by 48
Self-citation
Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes
Thal, L. J., Mishra, R. K., Gardner, E. L., Horowitz, S. G., Varmuza, S., & Makman, M. H. (1979) · Brain Research · doi:10.1016/0006-8993(79)90119-7 · Cited by 45
Centrally administered oligodeoxynucleotides in rats: occurrence of non-specific effects
Schöbitz, B., Pezeshki, G., Probst, J. C., Reul, J. M. H. M., Skutella, T., Stöhr, T., Holsboer, F., & Spanagel, R. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01014-5 · Cited by 43
BDNF is necessary for maintenance of noradrenergic innervations in the aged rat brain
Matsunaga, W., Shirokawa, T., & Isobe, K. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00093-9 · Cited by 42
Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization
Yaida, Y., & Nowak, T. S. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00100-p · Cited by 38
Spontaneous Behaviours of Rats are Differentially Affected by Substantia Nigra Infusions of Brain‐derived Neurotrophic Factor and Neurotrophin‐3
Martin-Iverson, M. T., & Altar, C. A. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01313.x · Cited by 32
Relation between motor asymmetry and direction of rotational behaviour under amphetamine and apomorphine in rats with unilateral degeneration of the nigrostriatal dopamine system
Ziegler, M., & Szechtman, H. (1990) · Behavioural Brain Research · doi:10.1016/0166-4328(90)90099-z · Cited by 32
Modulation of Nigrostriatal Dopaminergic Transmission by Antisense Oligodeoxynucleotide Against Brain-Derived Neurotrophic Factor
Lau, Y., Hao, R., Fung, Y. K., Fu, L.-S., Bishop, J. F., Pfeiffer, R. F., & Mouradian, M. M. (1998) · Neurochemical Research · doi:10.1023/a:1022482518292 · Cited by 16
Dopaminergic responses to striatal damage.
Howells, D. W., Liberatore, G. T., Wong, J. Y. F., & Donnan, G. A. (1996) · PubMed · Cited by 14
Self-citation
Rescue of axotomized rubrospinal neurons by brain-derived neurotrophic factor (BDNF) in the developing opossum, Didelphis virginiana
Wang, X. M., Terman, J. R., & Martin, G. F. (1999) · Developmental Brain Research · doi:10.1016/s0165-3806(99)00148-0 · Cited by 8
Dopaminergic responses to striatal damage
Howells, D. W. (1996) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00046-9 · Cited by 6
Self-citation
Dopaminergic pathways in the rat central nervous system and rotational behaviour
Funk, K. F., & Westermann, K. (1979) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(79)90003-0 · Cited by 3
Untitled work
Wang (1996) · doi:10.1002/(sici)1096-9861(19960318)366:4

Sorted by citations

Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504
Brain-Derived Neurotrophic Factor Is Required for the Establishment of the Proper Number of Dopaminergic Neurons in the Substantia Nigra Pars Compacta
Baquet, Z. C., Bickford, P. C., & Jones, K. R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4601-04.2005 · Cited by 318

See all 135

Authors: Porritt, M. J., Batchelor, P. E., & Howells, D. W.
Affiliations: The University of Melbourne (AU)
Corresponding author: Howells, D.W
ORCID: Porritt, M.J.
Batchelor, P.E.
Howells, D.W
Venue: Experimental Neurology
Publisher: Elsevier BV
Published: 2005-03
Volume: 192
Issue: 1
Pages: 226-234
ISSN: 0014-4886 (ISSN-L)
DOI: 10.1016/j.expneurol.2004.11.030
OpenAlex: W1985464631
Cited by: 135
References: 56
Citations by year: 2025: 7 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 4 · 2020: 8 · 2019: 3 · 2018: 10 · 2017: 9 · 2016: 6 · 2015: 10 · 2014: 5 · 2013: 6 · 2012: 11
FWCI: 4.06
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Experimental Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: Hospital Research Foundation
Austin Medical Research Foundation
National Health and Medical Research Council
National Medical Research Council
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords: brain-derived neurotrophic factor, substantia nigra pars compacta, dopaminergic neuron loss, Parkinson's disease, tyrosine hydroxylase, dopamine uptake, MPTP, 6-hydroxydopamine, apomorphine rotation, Parkinson's disease model
MeSH terms: Animals, Binding, Competitive, Cell Survival, Disease Models, Animal, Dopamine, Male, Mazindol, Nerve Degeneration, Neurons, Radioligand Assay, Receptors, Dopamine, RNA, Messenger, Substantia Nigra, Tyrosine 3-Monooxygenase, Down-Regulation, Oligonucleotides, Antisense, Cell Death, Rats, Sprague-Dawley, Neuroprotective Agents, Dopamine Uptake Inhibitors, Brain-Derived Neurotrophic Factor, Parkinsonian Disorders, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks